Jared A. Gollob
Duke University Medical Center Durham
NC 27710
USA
Name/email consistency: high
- Historic evidence and future directions in clinical trial therapy of solid tumors. Gollob, J.A., Bonomi, P. Oncology (Williston Park, N.Y.) (2006)
- Gene expression changes and signaling events associated with the direct antimelanoma effect of IFN-gamma. Gollob, J.A., Sciambi, C.J., Huang, Z., Dressman, H.K. Cancer Res. (2005)
- Sorafenib: scientific rationales for single-agent and combination therapy in clear-cell renal cell carcinoma. Gollob, J.A. Clinical. Genitourinary. Cancer (2005)
- Phase I trial of concurrent twice-weekly recombinant human interleukin-12 plus low-dose IL-2 in patients with melanoma or renal cell carcinoma. Gollob, J.A., Veenstra, K.G., Parker, R.A., Mier, J.W., McDermott, D.F., Clancy, D., Tutin, L., Koon, H., Atkins, M.B. J. Clin. Oncol. (2003)